Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $357.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Canaccord Genuity Group from $283.00 to $357.00 in a research report released on Monday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on the company. Evercore ISI lifted their […]
More Stories
Blackstone Mortgage Trust (NYSE:BXMT) Price Target Increased to $22.00 by Analysts at Wells Fargo & Company
Blackstone Mortgage Trust (NYSE:BXMT – Free Report) had its price target raised by Wells Fargo & Company from $19.00 to...
Truist Financial Boosts Banc of California (NYSE:BANC) Price Target to $16.00
Banc of California (NYSE:BANC – Free Report) had its price objective lifted by Truist Financial from $15.00 to $16.00 in...
Insider Selling: Nexstar Media Group, Inc. (NASDAQ:NXST) EVP Sells $472,717.44 in Stock
Nexstar Media Group, Inc. (NASDAQ:NXST – Get Free Report) EVP Blake Russell sold 2,782 shares of the business’s stock in...
Insider Selling: The Charles Schwab Co. (NYSE:SCHW) Director Sells $576,450.00 in Stock
The Charles Schwab Co. (NYSE:SCHW – Get Free Report) Director Carolyn Schwab-Pomerantz sold 9,000 shares of the company’s stock in...
Aris Mining Corporation (TSE:ARI) Director Sells C$309,522.00 in Stock
Aris Mining Corporation (TSE:ARI – Get Free Report) Director Douglas John Bowlby sold 47,400 shares of the business’s stock in...
Evergy (NYSE:EVRG) Now Covered by Analysts at Jefferies Financial Group
Jefferies Financial Group started coverage on shares of Evergy (NYSE:EVRG – Free Report) in a research report sent to investors...